Cambridge Investment Research Advisors, Inc. Editas Medicine, Inc. Transaction History
Cambridge Investment Research Advisors, Inc.
- $32.9 Billion
- Q2 2025
A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 176,604 shares of EDIT stock, worth $531,578. This represents 0.0% of its overall portfolio holdings.
Number of Shares
176,604
Previous 85,716
106.03%
Holding current value
$531,578
Previous $99,000
292.93%
% of portfolio
0.0%
Previous 0.0%
Shares
26 transactions
Others Institutions Holding EDIT
# of Institutions
214Shares Held
45.4MCall Options Held
476KPut Options Held
338K-
Black Rock Inc. New York, NY7.78MShares$23.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.16MShares$21.6 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.96MShares$5.91 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.88MShares$5.65 Million0.0% of portfolio
-
State Street Corp Boston, MA1.85MShares$5.56 Million0.0% of portfolio
About Editas Medicine, Inc.
- Ticker EDIT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 68,737,200
- Market Cap $207M
- Description
- Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...